Twincretin therapy for type 2 diabetes: how do two do?

[1]  B. Ludvik,et al.  Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial , 2021, The Lancet.

[2]  J. Rosenstock,et al.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. , 2021, The New England journal of medicine.

[3]  M. Horowitz,et al.  Glucagon‐like peptide‐1 receptor agonists and the appropriate measurement of gastric emptying , 2020, Diabetes, obesity & metabolism.

[4]  C. Malbert,et al.  Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady‐state concentrations , 2020, Diabetes, obesity & metabolism.

[5]  M. Christensen,et al.  The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review , 2019, International journal of molecular sciences.

[6]  M. Horowitz,et al.  Agonism of receptors in the gut–pancreas axis in type 2 diabetes: are two better than one? , 2018, The Lancet.

[7]  M. Horowitz,et al.  Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management , 2018, Diabetes Care.

[8]  J. Holst,et al.  GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study , 2018, Diabetologia.

[9]  K. Boye,et al.  GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries , 2017, Diabetes Therapy.

[10]  J. Holst,et al.  Roles of the Gut in Glucose Homeostasis , 2016, Diabetes Care.

[11]  A. Astrup,et al.  Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults , 2013, International Journal of Obesity.